ANIX Stock Analysis
AN
Uncovered
Anixa Biosciences Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The firm's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others. Its vaccine programs include the development of a preventative vaccine against triple-negative breast cancer (TNBC), the lethal form of breast cancer, as well other forms of breast cancer, and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell (CAR- T) technology that is focused on treating ovarian cancer, which is developed at its subsidiary, Certainty Therapeutics, Inc., and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.